CalciMedica reports Q2 EPS (40c) vs. (36c) last year

Cash, cash equivalents, and short-term investments were $18.0M as of June 30, 2025. The company expects its cash position to be sufficient to fund its current operating plan into the middle of 2026. “We have continued to spotlight the growing body of evidence supporting the development of Auxora for the treatment of AKI with respiratory failure, including publications in two peer-reviewed journals, multiple presentations at medical meetings, and a symposium at the 43rd Vicenza Course AKI-CRRT-EBPT and Critical Care Nephrology meeting. We look forward to the readout of our Phase 2 KOURAGE trial expected in early 2026,” said CEO Rachel Leheny. “Additionally, we are encouraged by our initial meeting with the FDA regarding our program in AP. The meeting was constructive, and we are eager to continue our discussions with the agency, with the objective of reaching alignment on a pivotal trial around the end of 2025.”